<DOC>
	<DOCNO>NCT00498654</DOCNO>
	<brief_summary>The purpose trial examine safety immunogenicity Ty800 oral vaccine healthy adult subject .</brief_summary>
	<brief_title>Dose Ranging Study Determine Safety , Reactogenicity Immunogenicity Typhoid Fever Vaccine ( Ty800 ) Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Typhoid Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Males Females age 18 55 year , inclusive Capable understand comply protocol requirement available duration protocol History malignancy , immunocompromised condition currently receive immunosuppressive treatment include systemic steroid History Typhoid Fever infection , vaccination typhoid fever participation Clinical Trial use S.typhi organism time History travel typhoid endemic region within last 5 year history raise child endemic area . Endemic region South East Asia , Indian Subcontinent , Africa Central South America include Mexico History persistent diarrhea , blood stool , peptic ulcer disease , inflammatory bowel disease Allergies sensitivities antibiotic , notably quinolones , penicillin , sulfonamide , cefalosporins chloramphenicol , component buffer solution , notably aspartame . People commercial food handler , day care worker , health care worker involve direct patient care . Also people young child 2 year age home household contact immunocompromised , pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Prevention Typhoid Fever Adult Travelers</keyword>
</DOC>